North Carolina’s life science community saw it all in 2015: billion-dollar deals, expansions, relocations, acquisitions, venture capital funding, an IPO, government grants, global accolades, a new pharmacy school and even two Nobel Prizes. There were a few partnering deals making headlines for North Carolina life science companies and technologies during 2015.
Here are some of the key ones.
- Boston’s Vertex Pharmaceuticals, a publicly traded company focused on cystic fibrosis therapies, announced plans to pay Durham-based Parion Sciences $80 million for rights to two of its experimental CF drugs, and to potentially pay Parion $1.2 billion, plus royalties, if certain milestones are achieved. NCBiotech provided early grant funding to support some of the research leading up to the Vertex deal with Parion, a 1999 spinout from the University of North Carolina at Chapel Hill. More.
- Duke University spin-out Chaperone Therapeutics of Research Triangle Park signed an exclusive, worldwide licensing agreement with Senhwa Biosciences of Taiwan for advanced small molecules that have therapeutic potential for neurodegenerative diseases caused by protein misfolding. More.
- Chaperone, which has received $200,000 in loan support from NCBiotech, also announced it was teaming up with the nonprofit ALS Therapy Development Institute of Cambridge, Mass., to explore potential treatments for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. More.
[Note: Check 5 links included with this post to review deals in other categories.]
See more at:
http://www.ncbiotech.org/article/parion-chaperone-among-ncs-2015-partnering-deals/151321#sthash.EqSMlPgH.dpuf
(C) N.C. Biotech Center
